2nd Jul 2018 12:30
LONDON (Alliance News) - Advanced Oncotherapy PLC said Monday that Sanjeev Pandya, Euan Thomson and Chris Nutting have stood down from the board.
The developer of proton therapy systems for cancer treatment also said that it will appoint Peter Sjostrand, Gabriel Urwitz, Zhang RenHua, Chunlin Han and Yuelong Huang as non-executive directors. Thomson and Nutting will continue to contribute to the company's development by becoming members of the Medical Advisory Board.
Mike Sinclair will remain executive chairman, Advanced Oncotherapy added.
Sjostrand, who will also become the company's vice-chairman, currently is a director of Sweden listed biotech company Active Biotech.
Urwitz is founding partner, managing partner and executive chairman of Nordic private equity firm Segulah Advisor AB. A consortium of shareholders led by Segulah owns 13% of Avanced Oncotherapy.
RenHua, Han and Huang will represent Liquid Harmony on the company's board.
RenHua is the co-founder, chief executive, and vice chairman of Realcan Pharmaceutical Co Ltd, a large distributor of medical drugs and equipment in China. Han serves as head of investment and financing for Realcan Pharmaceuticals Co Ltd. Huang serves as general manager of Medical Technology Department of Realcan Pharmaceuticals.
Advanced Oncotherapy said Liquid Harmony and the Han family's extensive knowledge and experience of rolling-out high-end medical equipment in China and internationally will be of great benefit to the company's commercialisation strategy.
Shares in Advanced Oncotherapy were down 3.2% at 46.00 pence each.
Related Shares:
AVO.L